Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study Of Niraparib In Patients With PALB2 Mutated Locally Advanced Or Metastatic Solid Tumors, Including Pancreatic Cancer

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of niraparib in patients with locally advanced or metastatic PALB2 (tPALB2) mutation solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05169437
Study ID: TMPS-101
Trial Phase: Phase II

Trial Sponsor: Tempus Labs
Therapies Used in This Trial: Niraparib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search